Abbott Laboratories financials
$100.95−0.03%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B | $34.61B | $31.90B | $30.58B | $27.39B | $20.85B |
| Gross profit | $25.01B | $23.24B | $22.13B | $24.51B | $24.54B | $19.61B | $18.67B | $17.87B | $14.98B | $11.76B |
| Gross margin | 56.4% | 55.4% | 55.2% | 56.1% | 57.0% | 56.6% | 58.5% | 58.4% | 54.7% | 56.4% |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B | $5.36B | $4.53B | $3.65B | $1.56B | $3.03B |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B | $4.50B | $3.69B | $2.37B | $477.0M | $1.40B |
| Net margin | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% | 11.6% | 7.7% | 1.7% | 6.7% |
| Diluted EPS | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 | $2.52 | $2.06 | $1.34 | $0.27 | $0.94 |
| EBITDA | $11.17B | $10.04B | $9.72B | $11.63B | $11.96B | $8.68B | $7.55B | $6.96B | $5.49B | $4.38B |
| Operating cash flow | $9.57B | $8.56B | $7.26B | $9.58B | $10.53B | $7.90B | $6.14B | $6.30B | $5.57B | $3.20B |
| Free cash flow | $7.39B | $6.35B | $5.06B | $7.80B | $8.65B | $5.72B | $4.50B | $4.91B | $4.43B | $2.08B |
| Diluted shares | 1,741.0M | 1,740.0M | 1,740.0M | 1,764.0M | 1,789.0M | 1,786.0M | 1,781.0M | 1,770.0M | 1,749.0M | 1,483.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.52B | $7.62B | $6.90B | $9.88B | $9.80B | $6.84B |
| Short-term investments | $417.0M | $351.0M | $383.0M | $288.0M | $450.0M | $310.0M |
| Total debt | $12.93B | $14.13B | $14.68B | $16.77B | $18.05B | $18.75B |
| Total assets | $86.71B | $81.41B | $73.21B | $74.44B | $75.20B | $72.55B |
| Total liabilities | $33.94B | $33.51B | $34.39B | $37.53B | $39.17B | $39.55B |
| Shareholders' equity | $52.77B | $47.90B | $38.83B | $36.91B | $36.02B | $33.00B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology